research use only
Cat.No.S8873
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV |
|---|---|
| Other CMV Inhibitors | Valaciclovir HCl Bisindolylmaleimide IV Brivudine (BVDU) |
|
In vitro |
DMSO
: 100 mg/mL
(174.65 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 572.55 | Formula | C29H28F4N4O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 917389-32-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | MK-8228 | Smiles | COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O | ||
| In vitro |
AIC246 blocks viral replication without inhibiting the synthesis of progeny HCMV DNA or viral proteins. It is one of the most potent anti-HCMV agents reported to date, with a cell culture EC50 in the one-digit nanomolar range (∼5 nM) and a selectivity index exceeding 15,000. |
|---|---|
| In vivo |
AIC246 treatment leads to a dose-dependent reduction of the HCMV titer in transplanted cells compared to that of the placebo-treated control group using the mouse xenograft model. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06118515 | Not yet recruiting | Congenital Cytomegalovirus Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
November 16 2023 | Phase 1 |
| NCT06057194 | Not yet recruiting | Infections Cytomegalovirus |
Maimónides Biomedical Research Institute of Córdoba|MERCK SHARP & DOHME DE ESPAÑA S.A. |
October 2023 | Phase 2 |
| NCT05446571 | Recruiting | Pregnant Women|CMV Infected Fetuses |
Assistance Publique - Hôpitaux de Paris |
October 20 2023 | Phase 3 |
| NCT06001320 | Recruiting | Kidney Transplant; Complications|CMV |
Virginia Commonwealth University|Merck Sharp & Dohme LLC |
September 25 2023 | Early Phase 1 |
| NCT05626530 | Recruiting | Cytomegalovirus Infections|Infection in Solid Organ Transplant Recipients|Neutropenia|Antiviral Toxicity |
Tufts Medical Center |
February 2 2023 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.